Literature DB >> 10200187

Subtype-specific effects of lithium on glutamate receptor function.

N B Karkanias1, R L Papke.   

Abstract

We report that substitution of sodium with lithium (Li+) in the extracellular solution causes subtype-specific changes in the inward and outward currents of glutamate receptors (GluRs), without a shift in reversal potential. Li+ produces an increase of inward and outward currents of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptors and decreases in the currents of kainate (KA) and N-methyl-D-aspartate receptors. The greatest effect of Li+ was observed with GluR3. A concentration-response curve for GluR3 reveals that the potentiation caused by Li+ is greatest at saturating agonist concentrations. GluR1, which shows no potentiation by Li+ at 100 microM KA, shows a small but significant potentiation at saturating KA and glutamate concentrations. The effects of Li+ on outward current, where Li+ is not the primary charge carrier, and the lack of reversal potential shift argue for a mechanism of potentiation not associated with Li+ permeation. This potentiation of current is specific for Li+ because rubidium, although causing an increase of inward current, shifted the reversal potential and did not increase outward current. The effects of Li+ are different for KA, a weak desensitizing agonist, and glutamate, a strong desensitizing agonist, suggesting that Li+ might interact with a mechanism of desensitization. By using cyclothiazide (CTZ) to reduce desensitization of GluR3, we find that for low concentrations of KA and glutamate potentiation of the response by a combination of CTZ and Li+ is no greater than by CTZ or Li+ alone. However, at high concentrations of agonist, the potentiation of the response by a combination of CTZ and Li+ is significantly greater than by CTZ or Li+ alone. This potentiation was additive for glutamate but not for KA. At high agonist concentration in the presence of CTZ, the intrinsically lower desensitization produced with KA-evoked responses may preclude Li+ from potentiating the current to the same degree as it can potentiate glutamate-evoked responses. The additive effects of CTZ and Li+ were unique to the flop variant of GluR3.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10200187     DOI: 10.1152/jn.1999.81.4.1506

Source DB:  PubMed          Journal:  J Neurophysiol        ISSN: 0022-3077            Impact factor:   2.714


  6 in total

1.  Autoantibodies against an extracellular peptide of the GluR3 subtype of AMPA receptors activate both homomeric and heteromeric AMPA receptor channels.

Authors:  Katayun Cohen-Kashi Malina; Yonatan Ganor; Mia Levite; Vivian I Teichberg
Journal:  Neurochem Res       Date:  2006-09-12       Impact factor: 3.996

2.  Na+-mediated coupling between AMPA receptors and KNa channels shapes synaptic transmission.

Authors:  Evanthia Nanou; Alexandros Kyriakatos; Arin Bhattacharjee; Leonard K Kaczmarek; Gustavo Paratcha; Abdeljabbar El Manira
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-18       Impact factor: 11.205

3.  Lithium acts as a potentiator of AMPAR currents in hippocampal CA1 cells by selectively increasing channel open probability.

Authors:  Christine Gebhardt; Stuart G Cull-Candy
Journal:  J Physiol       Date:  2010-08-31       Impact factor: 5.182

Review 4.  Glutamate receptor genes: susceptibility factors in schizophrenia and depressive disorders?

Authors:  Hans H Schiffer
Journal:  Mol Neurobiol       Date:  2002-04       Impact factor: 5.590

5.  Involvement of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail suspension test and forced swim test.

Authors:  Todd D Gould; Kelley C O'Donnell; Eliot R Dow; Jing Du; Guang Chen; Husseini K Manji
Journal:  Neuropharmacology       Date:  2007-11-17       Impact factor: 5.250

6.  Downregulation of calcium-dependent NMDA receptor desensitization by sodium-calcium exchangers: a role of membrane cholesterol.

Authors:  Dmitry A Sibarov; Ekaterina E Poguzhelskaya; Sergei M Antonov
Journal:  BMC Neurosci       Date:  2018-11-12       Impact factor: 3.288

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.